1-4 of 4
von willebrand disease type 2m
Close
Sort by
Journal Articles

A Tiered Management Program To Conserve Replacement Therapy Resources for a Rural Population of Women with Type 2M von Willebrand Disease during Labor and Delivery.

John T. Salter, MD, Amy D. Shapiro, MD, Matt Sulkin, Meadow Heiman, Anne Greist, MD, Patsy Yoder, Jennifer Maahs
Journal: Blood
Blood (2007) 110 (11): 3961.
https://doi.org/10.1182/blood.V110.11.3961.3961
Published: 2007
Journal Articles

A Prospective Comparision of Intranasal (I.N.) and Subcutaneous (S.C.) Desmopressin (DDAVP) Therapy in Type 2M Von Willebrand Disease (VWD).

Scott Herbert, MD, Rekha Parameswaran, MD, Amy D. Shapiro, MD, Jorge Di Paola, MD, Jon Winay, Chris Roberson, Anne Greist, MD
Journal: Blood
Blood (2006) 108 (11): 1035.
https://doi.org/10.1182/blood.V108.11.1035.1035
Published: 2006
Journal Articles

High Dose Intranasal Desmopressin (DDAVP) Therapy in Type 2M Von Willebrand Disease (VWD): A Prospective Open Label Trial.

Rekha Parameswaran, MD, Jorge Di Paola, MD, Lorrie Miller-Rice, MD, Anne Greist, MD, Amy D. Shapiro, MD
Journal: Blood
Blood (2005) 106 (11): 1783.
https://doi.org/10.1182/blood.V106.11.1783.1783
Published: 2005
Journal Articles

Increased Clearance Explains the Ultra-Large Multimers in Von Willebrand Disease Type 2M Vicenza; Lessons from Recombinant VWF Vicenza and Modeling of Multimer Catabolism.

András Gézsi, Gábor Balázsi, Krisztina Sallai, Adrienn Mohl, Eszter Nagy, PhD, Teréz Szabó, MD, J. Evan Sadler, MD, PhD, Imre Bodó, MD, PhD
Journal: Blood
Blood (2004) 104 (11): 3669.
https://doi.org/10.1182/blood.V104.11.3669.3669
Published: 2004